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ABSTRACT To understand further the weak molecular interactions between inhaled anesthetics and proteins, we studied
the character and dynamic consequences of halothane binding to bovine serum albumin (BSA) and myoglobin using
photoaffinity labeling and hydrogen-tritium exchange (HX). We find that halothane binds saturably and with submillimolar
affinity to BSA, but either nonspecifically or with considerably lower affinity to myoglobin. Titration of halothane binding with
guanidine hydrochloride suggested more protection of binding sites from solvent in BSA as compared with myoglobin.
Protection factors for slowly exchanging albumin hydrogens are increased in a concentration-dependent manner by up to
27-fold with 10 mM halothane, whereas more rapidly exchanging groups of albumin hydrogens have either unaltered or
decreased protection factors. Protection factors for slowly exchanging hydrogens in myoglobin are decreased by halothane,
suggesting destabilization through binding to an intermediate or completely unfolded conformer. These results demonstrate
the conformation dependence of halothane binding and clear dynamic consequences that correlate with the character of
binding in these model proteins. Preferential binding and stabilization of different conformational states may underlie
anesthetic-induced protein dysfunction, as well as provide an explanation for heterogeneity of action.
INTRODUCTION
It is now clear that volatile anesthetics can influence a wide
variety of biological functions, both at the integrated and at
the reductionist level (Alifimoff and Miller, 1993). How-
ever, it is less clear, and in fact an issue of considerable
debate, whether these widespread effects are mediated
through direct interactions with the protein component of
such systems or through actions on other components such
as lipid. Until recently, there have been few unambiguous
data for inhalational anesthetic binding to protein, a prereq-
uisite for a direct effect. A host of functional studies using
lipid-free preparations of firefly luciferase strongly suggest
a direct effect (Franks and Lieb, 1984), and halothane
photolabeling suggested specific binding (Evers et al.,
1995). On the other hand, a recent calorimetry study (Chiou
and Ueda, 1994) showed that anesthetics destabilize this
enzyme, suggesting the mechanism for inhibition of activity
is preferential binding to an unfolded conformer rather than
specific binding to the native, folded state. In other soluble
proteins, such as serum albumin, 19F-NMR (Dubois et al.,
1993), gas chromatographic partitioning analysis (Dubois
and Evers, 1992), and photoaffinity labeling (Eckenhoff and
Shuman, 1993) have all demonstrated saturable binding of
volatile anesthetics that disappears on unfolding the protein
with low pH conditions. Although the location of the spe-
cific halothane binding sites on bovine serum albumin
(BSA) was recently suggested by tryptophan fluorescence
quenching (Johansson et al., 1995), and then confirmed with
direct photoaffinity labeling (Eckenhoff, 1996), it is still not
clear whether these sites are a feature of the native, folded
state or whether they predominantly exist in a less folded,
molten state. Although differential scanning calorimetry
(DSC) experiments suggest stabilization of BSA by volatile
anesthetics (Tanner et al., 1997), thermal unfolding of this
protein is not reversible, making the interpretation of such
results difficult. Whether anesthetics stabilize or destabilize
proteins is of fundamental importance to an understanding
of their mechanism of action; differential binding to differ-
ent conformational states surely underlies anesthetic action
and perhaps the subtly unique actions of different anesthetics.
In this study, we examine the relationship between bind-
ing and protein stability in two soluble carrier proteins,
serum albumin and myoglobin. We use hydrogen exchange
(HX) to measure protein stability/dynamics for several rea-
sons. First, because exchange of the slowest hydrogens
occurs on exposure of these amide groups to solvent, their
exchange kinetics should reflect more complete unfolding
events and may be used as a measure of folded stability (Bai
et al., 1994). Furthermore, changes in HX rate are observed
with small shifts in the folded/unfolded equilibrium that
would produce no detectable change in the heat capacity or
optical signals (such as circular dichroism spectroscopy).
Second, HX can be performed under isothermal conditions,
avoiding the issue of unfolding reversibility and the tem-
perature dependence of binding enthalpy. Finally, concen-
trations of volatile anesthetics are easier to control in the
typical HX experiment than in DSC, again because of the
isothermal conditions. Our experiments continue to use
photoaffinity labeling (Eckenhoff and Shuman, 1993) to
measure binding, as it is the only available technique for
separation of specific from nonspecific binding for the
inhaled anesthetics, requires far less protein than 19F-NMR
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or gas chromatographic partitioning, and does not require
proximity of the anesthetic binding site to a reporter group,
such as an aromatic residue or spin label. Although photo-
labeling is commonly used for identification of proteins that
bind the ligand preferentially, or for localization of binding
sites within a protein, it can also be used to estimate binding
parameters (KD, Bmax, and Hill number) by titrating label
incorporation against unlabeled ligand concentration (com-
petition assay).
MATERIALS AND METHODS
BSA (essentially fatty acid free) and myoglobin were purchased from
Sigma Chemical Co. (St. Louis, MO) and used without further purification.
Halothane (2-bromo-2-chloro-1,1,1-trifluoroethane) was purchased from
Halocarbon Laboratories (Hackensack, NJ) and passed through an alumina
column before use to remove water and thymol. Tritiated water (specific
activity  100 mCi/ml) was from Amersham (Arlington Heights, IL).
[14C]Halothane (51 mCi/mmol) from DuPont-NEN (Boston, MA) was
diluted immediately in water to a 5 mM solution and reduced specific
activity of 3 mCi/mmol. All other chemicals were obtained from Sigma and
were of reagent grade.
Photoaffinity labeling
Halothane binding parameters were obtained from competition assays
using direct photoaffinity labeling of [14C]halothane (Eckenhoff and Shu-
man, 1993). Solutions of protein (generally 1 mg/ml) were prepared in
deoxygenated phosphate buffer (concentration and pH values given below
for individual experiments) and placed in 0.5-cm-path-length 2.0-ml quartz
cuvettes, together with increasing concentrations of either unlabeled halo-
thane (0–7 mM) or guanidine hydrochloride (0–3 M) prepared in the same
buffers and added from gas-tight Hamilton syringes (Reno, NV). [14C]ha-
lothane was also added as a small aliquot from another gas-tight syringe to
achieve 100 M in the cuvette. Halothane-containing solutions were
generally added to the cuvette last, to avoid loss into the gas space.
Cuvettes were exposed to the output of a low-pressure Hg(Ar) Oriel pencil
calibration lamp at 1 cm distance with constant stirring for 60 s. The
cuvette contents were then precipitated with ice-cold 10% trichloroacetic
acid (TCA), filtered through Whatman GF/B glass fiber filters, and washed
with 8 ml of cold 1% TCA. Incorporated dpm was determined using liquid
scintillation after incubation overnight. The effect of guanidine on both the
BSA and myoglobin folded fraction was determined with an Aviv 62 CD
spectrometer, at a protein concentration of 10 M in 10 mM K2PO4,
pH 7.0.
Hydrogen exchange
Protein was dissolved at 2–10 mg/ml in sodium phosphate buffer (20–100
mM) at pH 9 with 1 M guanidine hydrochloride and incubated with 5
mCi of 3H2O at least 18 h at room temperature to completely equilibrate
exchangeable amide hydrogens with solvent hydrogens. Aliquots were
removed to determine specific activity of 3H. Free 3HOH was removed
from the protein solution with a PD-10 (Sigma) gel filtration column to
initiate exchange-out, and this also facilitated a switch to the exchange-out
buffer. Because different proteins have different intrinsic hydrogen ex-
change rates, the exchange-out buffer was adjusted for each protein to
allow focus on the slow hydrogens (the last 20 or so to exchange) in a
convenient time window (less than 10 h). For BSA, the exchange-out
conditions were 100 mM sodium phosphate at pH 7.4 with 1 M guanidine
hydrochloride and 38°C. To focus on groups of more rapidly exchanging
hydrogens, the intrinsic HX rate was slowed in some exchange-out exper-
iments by reducing the pH to 6.0 or 7.0 and lowering the temperature to
23°C; guanidine was also eliminated in these experiments. Exchange-out
conditions for myoglobin were similar to BSA, except that guanidine was
excluded and the pH was raised to 8.0. After recovery from the column, the
protein solution was immediately transferred to prefilled Hamilton gas-
tight syringes (with or without halothane) equipped with repeaters, and
aliquots were delivered into ice-cold 10% TCA at timed intervals. The
precipitated protein was vacuum filtered through Whatman GF/B filters
and washed with 8 ml of ice-cold 1% TCA. The entire precipitation/
filtration procedure was routinely accomplished in 10 s or less, and loss of
hydrogens in this brief time period was excluded as a possibility by
comparing retained activity in some parallel protein samples run through a
second column according to the technique of Englander and Englander
(1984). After equilibration of the filters with fluor overnight, retained 3H
was determined with scintillation counting. Protein concentration of par-
allel repeater aliquots was determined by absorbance at 280 nm using
extinction coefficients of 45,000 cm1 M1 for BSA and 30,400 cm1
M1 for myoglobin. Small (5–10 l) samples of the exchange-in solution
were precipitated as above to assure equilibration of all exchangeable
hydrogens.
Data analysis
Binding parameters were determined from a nonlinear least squares fit of
the competition data to sigmoid curves of negative and variable slope using
InPlot Prizm (v2.01) software. Global exchange-out curves for large pro-
teins such as BSA result from the exchange of numerous individual or
grouped hydrogens, each exchanging with their own time constants. There-
fore, as global exchange is a complex multiexponential function with
unknown components, we chose not to arbitrarily fit the data to obtain
global exchange-out rates. Rather, protection factors for given hydrogens
were determined from the data. Assuming horizontal equivalence of hy-
drogen exchange (the nth hydrogen to exchange is the same with and
without anesthetic), protection factor ratios were estimated by dividing the
time required for a given hydrogen to exchange under the differing con-
ditions (e.g., with and without anesthetic) and were determined for the last
three to five hydrogens in common for the two conditions. Protection factor




Unlabeled halothane competed with label incorporation into
BSA with an IC50 of 0.2 mM and Hill coefficient of 0.7
(Fig. 1), similar to what we have previously reported for this
protein. Apparent dissociation constants (KD) can be ob-
tained using the following equation:
KI IC50/1 14C	halothane	/KD
and when the competing ligands are the same:
KD IC50 14C	halothane	
Therefore, the apparent KD for halothane photolabeling of
BSA is 0.1 mM. The conformation dependence of this
specific binding has been suggested by our previous results
with different pH values (Eckenhoff and Shuman, 1993) but
also shown here by the effect of guanidine. Fig. 2 shows
that, although low concentrations of guanidine had a mini-
mal effect on label incorporation, progressively higher con-
centrations significantly inhibited labeling. The guanidine
IC50 was 1.8 
 0.2 M, slightly less than that causing a 50%
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loss in helicity as determined with circular dichroism spec-
troscopy (2.2 
 0.03 M; Fig. 2.).
Fig. 3 shows 3H exchange-out from BSA in different
concentrations of halothane. Halothane decreases the HX
rate of these slow amide hydrogens in a concentration-
dependent fashion, implying a stabilization of the protein
through preferential binding to the native, folded state,
consistent with the conformational dependence of binding
as determined above (Fig. 2). PFRs and the corresponding
free energy changes are given in Table 1. Whereas the
calculated G values assume that these last 40 BSA
hydrogens exchange through the same global unfolding
event, they are remarkably consistent with the estimated
G for halothane stabilization of BSA using DSC (Tanner
et al., 1997). By lowering the pH to slow chemical exchange
of hydrogens, and excluding guanidine, so that a group of
more rapidly exchanging, and presumably more solvent-
exposed, BSA hydrogens can be probed, it could be seen
that 10 mM halothane significantly accelerated exchange of
the group of hydrogens from 350 to 170, while produc-
ing no significant effect on the group of BSA hydrogens
from 170 to 120 (Fig. 4). This is in sharp contrast to the
effect of this concentration of halothane on the slower
exchanging group of amide hydrogens (100; Fig. 3) and
suggests that there are differential intramolecular effects of
halothane binding in this protein.
Myoglobin
As shown in Fig. 5, the labeling of myoglobin by100 M
[14C]halothane is at least 50-fold less than that of BSA, but
there is some inhibition of label incorporation by high
concentrations of unlabeled halothane, suggesting the pres-
ence of a weak specific component to the total binding.
Thus, although a halothane IC50 value for myoglobin cannot
be determined with confidence, it is in excess of 10 mM. On
the other hand, Fig. 6 shows almost complete inhibition of
label incorporation by guanidine concentrations (0.3M)
that produce no change in myoglobin helicity (guanidine
IC50 of 1.7  0.1 M). This is interpreted to indicate that, in
contrast to BSA, most halothane binding sites in myoglobin
are nonspecific and more solvent-exposed. If one assumes
that guanidine unfolds proteins by recruitment of weak
FIGURE 2 Similar to Fig. 1, except guanidine was used as a competing
ligand for [14C]halothane photolabeling of BSA (; fitted IC50  2.2 

0.03 M). Also shown is the percent folded from ellipticity at 222 nm (f;
fitted IC50  1.8 
 0.1 M).
FIGURE 3 Hydrogen-tritium exchange-out from serum albumin at pH
7.4, 1 M guanidine, and 38°C, and the effect of added halothane. From the
bottom, the curves are 0 mM, 1 mM, 3 mM, and 10 mM halothane.
TABLE 1 Protection factor ratios and free energy change
Protein [Halothane] Hydrogen range* PFR# G§
BSA 1 mM 4–8 2.0 0.42
BSA 3 mM 9–13 4.7 0.96
BSA 10 mM 34–38 27 2.04
Myoglobin 1 mM 18–20 0.80 0.14
Myoglobin 10 mM 18–20 0.25 0.86
*Range of hydrogens for which protection factors were determined.
#Time (min) for control exchange of H above divided by that for halothane.
§In kcal/mol protein.
FIGURE 1 Competition curve for [14C]halothane (100 M) labeling of
bovine serum albumin, using unlabeled halothane as a competitor.Points
are the mean of at least three experiments, with three replicates, and the
line is a nonlinear least squares fit to Hill plots with variable negative slope.
IC50  0.18 (95% C.I.  0.15–0.22); Hill  1.3 
 0.12.
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binding sites in the progressively more unfolded states
(Nozaki and Tanford, 1970), competition between guani-
dine and halothane would imply that the anesthetic is also
binding to analogous sites in the unfolded state. Like gua-
nidine, then, one might expect halothane to destabilize
myoglobin, which is confirmed by the HX results shown in
Fig. 7. Although 1 mM halothane had only a minor effect on
exchange-out from myoglobin, 10 mM halothane decreased
protection factors for hydrogens 18–20 by approximately
fourfold. The exchange of more rapidly exchanging hydro-
gens (100–20) was also increased by 10 mM hydrogen (data
not shown).
DISCUSSION
Photoaffinity labeling clearly distinguished between these
two soluble proteins with similar stability, showing at least
a 50-fold lower affinity of myoglobin for halothane. Precise
stoichiometry is difficult to determine from photoaffinity
competition assays, but estimates are possible when using
the same ligand as the competitor by recalculating the
specific activity of the label at the IC50 and correcting the
incorporation for this lower specific activity. Thus, for BSA,
the stoichiometry at IC50 is 2.7 mol halothane/mol BSA,
or an estimated Bmax of 5.4 mol/mol. This is consistent
with our preliminary DSC results (Tanner et al., 1997),
which suggested a lower limit of approximately five sites,
and isothermal titration calorimetry results in albumin with
a similar halogenated alkane anesthetic, chloroform (Ueda
and Yamanaka, 1997), suggesting four higher-affinity sites
and several lower-affinity ones. The uncertainty of IC50 for
myoglobin precludes confidence in a calculated Bmax value,
but data shown in Fig. 4 suggest a stoichiometry of at least
5 mol/mol.
Although the mechanism of guanidine inhibition of pho-
tolabeling is not clear at this point, the data are consistent
FIGURE 4 Hydrogen-tritium exchange from BSA at pH 6.0 (E and F)
and pH 7.0 ( and f) at 23°C. E and , control; F and f, 10 mM
halothane. Each set represents three individual experiments, with data
points for each group normalized to the average 5-min point. Standard error
bars are shown.
FIGURE 5 Competition curve as in Fig. 1, except for myoglobin. The
line represents the best fit, but parameters are not reported because of poor
confidence in the 50% inhibition region, and higher halothane concentra-
tions were not used because of solubility limitations and UV-screening
effects of high halothane concentrations. Note very low labeling stoichi-
ometry at this low [14C]halothane control concentration (100 M).
FIGURE 6 Guanidine titration of [14C]halothane photolabeling of myo-
globin demonstrates near complete inhibition at [guanidine]  0.3 M (E),
far lower than required for unfolding this protein based on ellipticity at 222
nm (F; guanidine IC50  1.7 
 0.1 M).
FIGURE 7 Hydrogen-tritium exchange of myoglobin at pH 8 and 38°C
and the effect of added halothane. From the bottom, curves are 10 mM, 1
mM, and 0 mM halothane.
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with competition at nonspecific binding sites. Although
halothane and guanidine clearly have different polar char-
acter, nonspecific binding is, by definition, characterized by
very low interaction energy and should therefore be rela-
tively nonselective. Guanidine titration of halothane pho-
toaffinity labeling allowed separation of at least two classes
of binding sites in these two model proteins, and perhaps a
basis for the different binding character. One class of site
appears to be freely exposed to solvent guanidine and does
not distinguish between solvent halothane and guanidine,
and a second group of sites is more protected from solvent
guanidine, presumably in internal, hydrophobic environ-
ments. As the protein becomes progressively more exposed
with the increasing concentrations of guanidine, there is less
protection for the hydrophobic environments from the sol-
vent, effectively removing this more specific class of halo-
thane binding site. It is predicted that specific sites are a
feature of native tertiary structure, which is likely the basis
for the slightly lower guanidine IC50 for binding as com-
pared with helicity, a measure of secondary structure. BSA
is an example of a protein that contains predominantly this
specific class of site. Binding to myoglobin, on the other
hand, is entirely lost at a guanidine concentration resulting
in no loss of helicity, suggesting that sites are more solvent-
exposed. Therefore, these results would appear to implicate
hydrophobic cavities as the basis for preferred binding to
BSA, essentially an entropic event. Weak electrostatics may
also contribute, however, as we have shown that at least two
of the halothane binding sites contain tryptophan residues
(Johansson et al., 1995; Eckenhoff, 1996), and the van’t
Hoff relationship for halothane binding to these regions
using tryptophan fluorescence quenching yields a H of
1 kcal/mol (Johansson and Eckenhoff, 1997). Thus, the
results are most consistent with binding of multiple halo-
thane molecules on these two proteins but at sites of differ-
ent character and degree of solvent exposure. Furthermore,
the clear distinction between the binding character in these
proteins gives additional confidence that halothane photo-
labeling is reliably reporting sites of equilibrium distribution.
The HX results show that this conformation-dependent
binding of halothane to protein has clear consequences in
terms of overall protein stability as reflected by hydrogen
exchange behavior. The protection factor refers to the dif-
ference in exchange kinetics of a given population of amide
hydrogens in a peptide relative to that of a completely
exposed, non-hydrogen-bonded amide hydrogen (half-time
of 104 s at pH 7 and 20°C) and normally ranges over
several orders of magnitude. The last hydrogens to ex-
change are thought to do so through a cooperative and
transient but global unfolding process, so native-state pro-
tection factors (PFNative) should be proportional to 1/Kunfold.
Making allowances for the pH and temperature effects on
chemical exchange rates (Englander and Englander, 1984),
our results of greater than 500 min for exchange of the last
20 hydrogens of myoglobin at 38°C and pH 8 translate to
protection factors of 1010, yielding an unfolding Go of
13 kcal/mol, consistent with previous results in myoglo-
bin (Pace and Vanderburg, 1979). BSA appears to be even
more stable, 1 M guanidine being necessary to bring this
population of hydrogens into the same time frame. The
slowing of hydrogen exchange (increase in protection fac-
tors) in BSA confirms preferential binding of halothane to
the native, folded conformation of this protein as predicted
by the guanidine titration (this study), the effect of pH on
halothane binding (Eckenhoff and Shuman, 1993), and the
preliminary calorimetry results (Tanner et al., 1997).
Assuming that exposure of the slowly exchanging hydro-
gens is a result of global unfolding, and that halothane binds
predominantly to independent sites of identical affinity in
the native form of BSA, then the ratio of protection factors
(PFHalothane/PFControl or PFR) for the slowest hydrogens
would be predicted to be (1  [halothane]/KD)n, where n is
the number of binding sites and KD is the dissociation
constant for halothane binding to native state of BSA. Using
our experimentally derived KD of 0.1 mM and assuming, for
the moment, a single site, 10 mM halothane is predicted to
produce a 100-fold change in PF, 3 mM halothane 30-
fold, and 1 mM halothane 10-fold. As the observed
changes in PF in this study are all four- to fivefold lower
than this, either the actual KD is higher than 0.1 mM or these
BSA hydrogens are exchanging through less than global
unfolding events. The discrepancy between measured and
predicted changes in PF is made much larger when consid-
ering that evidence suggests multiple halothane binding
sites. Photolabeling KD values are indeed an underestima-
tion of true equilibrium values, probably because of irre-
versible depletion of sites at high unlabeled halothane con-
centrations. The magnitude could be as large as tenfold, as
shown by 19F-NMR spectroscopy (Dubois and Evers, 1992)
or tryptophan fluorescence quenching (Johansson et al.,
1995) studies, which estimated KD values for halothane
binding to BSA of1 mM. Even using this 1 mM KD value,
however, 10 mM halothane should change PF by a factor of
105 if all five sites are considered. Although the five BSA
halothane binding sites probably have different KD values, it
seems likely that at least a portion of the last 40 hydrogens
to exchange out of BSA do so through less than global
unfolding events.
Interestingly, halothane has a different influence on the
protection of more rapidly exchanging BSA amide hydro-
gens. In the most rapidly exchanging population probed in
this study, we find approximately a twofold decrease in
protection factor, implying that microstability, or rapid local
fluctuations in at least some regions of BSA, is modulated
differently by the anesthetic than macrostability. It is not yet
clear whether this represents a large localized change in
BSA structure or dynamics on binding halothane or a
smaller more widespread influence. This distinction may be
important if protein activity correlates better with local, as
opposed to global, motions.
On the other hand, myoglobin, also a very soluble carrier
protein, binds halothane poorly (as indicated by photolabel-
ing affinity) and in a way that only accelerates HX. This
destabilization suggests preferential binding to an unfolded
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form of the protein. Whether the preferential binding is to
the completely unfolded form of myoglobin or to an inter-
mediate is not yet clear, but our previous results suggest the
latter. In poly-(L-lysine), for example, the pH 12 -helical
conformation was photolabeled by halothane to a consider-
ably greater stoichiometry and affinity than the pH 7 ran-
dom coil form (Eckenhoff and Shuman, 1993), and a chain
length dependence to this binding implied the requirement
for supersecondary structure in addition to secondary struc-
ture (Johansson and Eckenhoff, 1996). Preferential binding
to an intermediate implies that, although supersecondary
structure is necessary to create a (hydrophobic) binding site,
native tertiary structure essentially precludes binding, pre-
sumably due to steric and/or dynamic constraints. The prob-
ability of such steric constraints to binding in myoglobin is
suggested by x-ray crystallographic evidence that places
only the smaller anesthetics dichloromethane, cyclopro-
pane, or xenon in the occupied heme cavity (Schoenborn,
1967, 1976; Tilton et al., 1984).
It is as yet difficult to reconcile these results in model
proteins with a general model of anesthetic interaction with
more functionally relevant proteins, and such attempts are
best viewed with caution. Nevertheless, some intriguing
observations can be made. For example, pressure (100–200
atm) antagonizes anesthesia (Wann and MacDonald, 1988)
and also reduces the stability of most proteins (Weber and
Drickamer, 1983), because of a lower apparent molecular
volume in the unfolded state. Therefore, at the molecular
level, pressure would be predicted to antagonize events
resulting in stabilization and enhance destabilization influ-
ences, suggesting that stabilizing events in at least some
proteins are important in producing the anesthetic state, or at
least in reflecting relevant anesthetic-protein interactions.
Likewise, decreasing temperature increases volatile anes-
thetic potency (independent of the effect on solubility)
(Franks and Lieb, 1996) and increases protein stability (at
least in the 20–40°C range) (Privalov, 1979), also consis-
tent with stabilization being a pharmacologically important
mode of anesthetic/protein interaction. Finally, the some-
what higher affinity of the binding interaction resulting in
stabilization events (e.g., BSA) is much closer to the con-
centration required to produce anesthesia in animals (0.2–
0.4 mM), although the necessary magnitudes of stabiliza-
tion, the domains stabilized, or the proteins stabilized are by
no means clear at this point.
Although it may be attractive to speculate that stabiliza-
tion is involved in the action of anesthetics, it is interesting
to note that other attempts to characterize the dynamic
consequences of anesthetic-protein interactions have found
that anesthetics tend to increase dynamics (Bigelow and
Thomas, 1987; Abadji et al., 1994; Cobb et al., 1990). It
may be important to point out that these studies were of
membrane protein (Ca2 ATPase, nicotinic acetylcholine
receptor, and erythrocyte anion exchange protein) and that
the time domain examined was considerably faster than
probed here. Given that halothane had different effects on
different groups of hydrogens in serum albumin, it is pos-
sible that these studies in membrane protein reflect local
events and that it is not clear in what direction, or even if,
global stability was altered.
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